Atai Life Sciences Raises $25 Million

German entrepreneur and investor Christian Angermayer creates Atai Life Sciences and raises $25 million to study the therapeutic effects of psychedelic drugs on depression and other mental illnesses.

October 2018

Christian Angermayer creates Atai Life Sciences to study the therapeutic effects of psychedelics on depression and other mental illnesses. So far he has raised $25 million from investors. Angermayer is already an investor in COMPASS Pathways and sees Atai focusing on financing similar research.